

Tuberculosis (TB) in Hospital: Infection Prevention Policy

Department / Service:	Infection Prevention and Control
Originator:	Lara Bailey (Infection Prevention and Control)
Accountable Director:	Sarah Shingler (Director of Infection Prevention and Control)
Approved by:	Trust Infection Prevention and Control Committee
Date of approval:	2 ND November 2023
First Revision Due	2 nd November 2026
This is the most current document and should be used until a revised version is in place :	
Target Organisation(s)	Worcestershire Acute Hospitals NHS Trust
Target Departments	All Clinical Departments
Target staff categories	All staff

Policy Overview:

Outline of infection prevention measures needed for managing TB cases in hospital. Also includes background information on TB, laboratory diagnosis, risk assessment to determine infectivity and likelihood of multi-drug resistance. Allocation of isolation facilities.

Key amendments to this policy

Date	Amendment	Approved by:
Dec 2019	Re write of policy. Approved for three years at TIPCC	TIPCC
Sept 2023	Various amendments made to the policy: <ul style="list-style-type: none"> • Contents page updated. • Name of Accountable Director changed. • Appendices A-E updated. • Removed Appendix F • Section 1.4 updated with recent annual total TB rates in West Midlands and England. • Section 4 – changed name of the Infection Prevention Team to Infection Prevention and Control Team throughout document. • Section 4 – added responsibility and duties for Occupational Health Department (OHD) • Section 5.1 – Name of TB Lead Physician changed. • Public Health England changed to UK Health Security Agency (UKHSA) throughout document. • Section 5.8.1 updated details of the local UKHSA Health Protection Team (HPT) • Section 9 – references updated and throughout document. • Section 10.3 – consultation list updated. • Supporting document 1 – EIA updated to reflect new format. 	TIPCC

Contents page:

1. Introduction
 - 1.1. Tuberculosis (TB)
 - 1.2. Multi-Drug Resistant Tuberculosis (MDR-TB)
 - 1.3. Extensively Drug Resistant Tuberculosis (XDR-TB)
 - 1.4. Epidemiology
2. Scope of this document
3. Definitions
4. Responsibility and Duties
5. Policy detail
 - 5.1. TB Laboratory Service
 - 5.2. Management of Suspected Tuberculosis
 - 5.2.1. How Infectious?
 - 5.2.2. Likelihood of Multi-Drug Resistant Tuberculosis (MDR-TB)
 - 5.3. Isolation of Suspected and Confirmed Tuberculosis Cases
 - 5.3.1. Levels of Isolation Required
 - 5.3.2. Allocation of Isolation Facilities
 - 5.3.3. Length of Isolation Precautions
 - 5.3.4. Patients Requiring Ventilation/General Intensive Care Unit
 - 5.3.5. Other Infection Control Issues During Isolation Period
 - 5.3.5.1. Crockery
 - 5.3.5.2. Coughing
 - 5.3.5.3. Waste
 - 5.3.5.4. Bodies
 - 5.4. Bronchoscopy and Other Aerosol Generating Procedures (AGPs)
 - 5.5. Healthcare Workers Protection
 - 5.5.1. Personal Protective Equipment (PPE)
 - 5.5.2. Occupational Health / Staff Vaccination
 - 5.5.3. Postmortems / Mortuary Staff
 - 5.6. Visitors
 - 5.7. Contact Tracing
 - 5.7.1. Community
 - 5.7.2. Hospital
 - 5.7.2.1. Hospital Patients
 - 5.7.2.2. Healthcare Workers
 - 5.8. Notification of Suspected or Confirmed Cases
 - 5.8.1. Statutory Notification
 - 5.8.2. TB Nurse Specialists
 - 5.9. Discharge Policy
 - 5.9.1. Patients with MDR-TB
6. Implementation of key document
 - 6.1. Plan for implementation

- 6.2. Dissemination
- 6.3. Training and awareness
- 7. Monitoring and compliance
- 8. Policy review
- 9. References
- 10. Background
 - 10.1. Equality requirements
 - 10.2. Financial Risk Assessment
 - 10.3. Consultation Process
 - 10.4. Approval Process

Appendices

[Appendix A Countries with a high incidence of MDR-TB](#)

[Appendix B Draft letter for patients present on the same ward as a case of infectious tuberculosis, and where the contact is not considered to be at any significant risk](#)

[Appendix C Draft letter for a patient's general practitioner and consultant following a patient's exposure to a patient with infectious tuberculosis on Trust premises](#)

[Appendix D Immunocompromised patients as defined by 'Immunisation against infectious disease' \(The Green Book\)](#)

[Appendix E TB Quick Action Guide](#)

Supporting Documents

Supporting Document 1	Equality Impact Assessment
Supporting Document 2	Financial Risk Assessment

1. Introduction

1.1. Tuberculosis (TB)

Tuberculosis (TB) is a chronic, progressive infection which most commonly affects the respiratory tract but can involve any organ of the body. Most cases of tuberculosis are caused by the bacterium *Mycobacterium tuberculosis* and a few by *Mycobacterium bovis* or *Mycobacterium africanum*. **It is a notifiable disease.**

TB can be transmitted from person-to-person via respiratory droplets, therefore certain infection prevention procedures should be employed when caring for a patient with known or suspected TB and these are highlighted in this policy. Methods of detecting this infection using laboratory tests are also outlined as these will help to determine the degree of infectivity.

Most patients with TB can be treated at home. Some require hospital admission for severe illness, adverse effects of chemotherapy, compliance, or social reasons (especially if drug-resistant TB is suspected or confirmed).

1.2. Multi-Drug Resistant Tuberculosis (MDR-TB)

MDR-TB is defined as *Mycobacterium tuberculosis* that is resistant to both rifampicin and isoniazid (two key antibiotics used to treat TB) with or without additional drug resistance. The incidence of multi-drug resistant TB in the UK is 2.4%, based on testing of laboratory isolates (UKHSA, 2021). Since it is unusual to have rifampicin resistance alone, if this is detected using a rapid molecular method then multi-drug resistance is inferred, whilst full sensitivity data are awaited.

Although MDR-TB is no more infectious than fully drug susceptible TB, the consequences of acquiring MDR-TB are much more serious. This is due to the greater difficulty and cost of treating it, with prolonged infectivity and the risk of much poorer outcomes.

This policy outlines how to make a risk assessment to identify patients suspected with MDR-TB and infection control measures that are appropriate for these patients.

1.3. Extensively Drug Resistant Tuberculosis (XDR-TB)

XDR-TB is defined as MDR-TB that is also extensively resistant to second line drugs (fluoroquinolones and either capreomycin, kanamycin or amikacin). These strains were first reported in Kwazulu-Natal, South Africa and have been associated with a higher mortality (Ghandi *et al.*, 2006; Raviglione *et al.*, 2007). The first UK case of XDR-TB was detected in Glasgow in 2008.

1.4. Epidemiology

TB affects one third of the world's population. Areas worst affected are where rates of poverty and HIV infection are highest. The UK is now considered to be a low incidence country, but there is considerable regional variation in rates of TB with a higher incidence in urban areas.

Individuals at higher risk of infection include those born in countries with a high incidence of TB (more than 40 per 100,000 population), children of those born in high incidence countries, contacts of known TB cases, HIV patients, alcohol dependent individuals and the homeless.

In 2021 the TB notification rate in England was 7.8 per 100,000 population. London accounts for most cases reported (17.8 per 100,000 population), followed by the Midlands (8.5 per 100,000) (UKHSA, 2023).

Annual Total TB rates (UKHSA, 2023)		
	2020	2021
West Midlands	548	569
England	4125	4429

2. Scope of this document

The purpose of these guidelines is to ensure that all staff caring for patients with known or suspected TB are aware of the processes to follow to:

- Improve individual patient outcomes and recovery from this infection and its associated complications.
- Reduce / eradicate opportunities for transmission to other patients / staff.

These guidelines should be read in conjunction with:

- a) Isolation and Bed Management Policy
- b) Management of Healthcare Waste Policy

These guidelines are intended for use by all Medical, Nursing, Allied Health staff and Managers including all temporary, locum and contracted staff. Where appropriate it should be referred to by all volunteer staff.

3. Definitions

MDR-TB

Mycobacterium tuberculosis that is resistant to both rifampicin and isoniazid (two key antibiotics used to treat TB) (see 1.2)

XDR-TB

MDR-TB that is also extensively resistant to second line drugs (see 1.3)

CCDC:

Consultant in Communicable Disease Control. Usually a Public Health Consultant.

UKHSA:

UK Health Security Agency (formerly known as Public Health England – PHE).

4. Responsibility and Duties

Chief Executive

The Chief Executive is ultimately accountable for infection prevention and control ensuring that effective arrangements are in place to reduce the spread of Tuberculosis and ensure that affected patients are managed appropriately to improve outcome, prevent cross-infection, and reduce morbidity/mortality.

Director of Infection Prevention and Control (DIPC)

As set out in the Chief Medical Officer's document 'Winning Ways' (2003) and Health and Social Care Act (2008) the DIPC is accountable directly to the Chief Executive and Trust Board on all matters relating to the prevention and control of healthcare associated infections (HCAIs)

Infection Prevention and Control Team (IPCT)

The IPCT is responsible for ensuring that this document reflects national guidance, clinical evidence, and best practice, and that this is disseminated throughout the Trust. The IPCT is responsible for co-ordinating the compliance monitoring of these procedures and ensuring that appropriate remedial actions are taken if compliance is inadequate.

Occupational Health Department (OHD)

The OHD are responsible for ensuring that healthcare workers (HCWs) have the appropriate pre-employment checks carried out prior to the commencement of employment within the Trust.

Clinical Leads and all Managers

Clinical Leads and all Managers are responsible for ensuring that these guidelines are made available to all appropriate staff and that staff comply with them on a day-to-day basis.

Qualified staff are responsible for ensuring their practice, and that of any unqualified staff they manage, comply with these guidelines and that they receive adequate training and support.

5. Policy Detail

5.1. TB Laboratory Service

Specimens from patients with suspected or confirmed TB should be sent in sealed specimen bags. Clinical details should be clearly stated on the form so that appropriate tests can be performed in the laboratory. If MDR-TB is suspected, please state this also.

Please see the pathology tests A-Z for further information on microbiological sampling:
<https://www2.worcsacute.nhs.uk/healthprofessionals/pathology/pathology-tests-a-to-z/?catid=2111>

5.1.1. Specimens

Microscopy and culture for Mycobacteria may be performed on these specimens:

Site of Infection	Specimens for microscopy & / or culture
Respiratory tract	Sputum (only when requested) Bronchial alveolar lavage / washings (all) Pleural Biopsy* Pleural fluid (only when requested)
Lymph Node	Node or aspirate*
Bone / joint	Biopsy material* Pus Joint fluid
Gastrointestinal	Biopsy material* Ascitic fluid (only when requested)
Disseminated / Miliary TB	Bronchial washings Liver biopsy* Bone marrow* Citrated blood sample Early morning urines (X3)
Central nervous system	CSF
Skin	Skin biopsy*
Pericardium	Pericardial fluid
Cold / liver abscess	Tissue sample*
Renal tract	Tissue sample* Early morning urine (X3)

*NOTE: Tissue specimens should not be placed in formalin if culture is required. However, for histological diagnosis of tuberculosis tissue specimens should be placed in formalin pots and sent to histopathology. Culture is not possible once the specimen is placed in formalin.

5.1.2. PCR for TB detection and rifampicin resistance

Molecular tests for *M. tuberculosis* complex and rifampicin resistance must be discussed with the duty microbiologist. They will be considered in the following circumstances:

1. From smear positive sputum if rapid confirmation of a TB diagnosis would alter the patient's care or before conducting a large contact-tracing initiative.
2. From other samples only after discussion with the duty microbiologist.

A negative PCR does not rule out TB, especially from specimens such as CSF or smear negative sputum. Treatment should be commenced on clinical grounds in these circumstances.

5.1.3. Clinical advice

Microbiology:

Clinical microbiology and infection prevention advice is available from the duty microbiologist during the day (9am-5pm) and out of hours the on-call microbiologist is available through switchboard for urgent queries.

Infection Prevention and Control Team (IPCT):

The infection prevention and control nurses are available from 8am – 4pm Monday to Saturday for infection prevention and control advice on either 01905 733 092 (WRH) or 01527 512 185 (ALX)

TB Nursing Team:

The TB Specialist nursing team are available on 01562 512 316 from 9am – 5pm Monday to Friday for advice. Email wah-tr.tb nursingteam@nhs.net

TB Lead Chest Physician:

Cases of suspected pulmonary TB should be discussed with the TB Lead Chest Physician: Dr Gulfam Mussawar.

Infectious Disease Physicians:

Cases of suspected extra-pulmonary TB should be discussed with the Infectious Diseases team: Dr Mark Roberts or Dr Mirella Ling.
Email referrals to wah-tr.idreferrals@nhs.net

5.2. Management of Suspected Tuberculosis

Undertake a risk assessment for TB (as below referring also to Appendix E)

Cough for more than 3 weeks – Consider TB!

Especially if from high incidence country or ethnic group, immunocompromised, chronic alcohol dependence, or social deprivation.

HIV & unexplained chest infiltrates – Consider TB!

*****ISOLATE ON SUSPICION OF INFECTION. DO NOT WAIT FOR MICROBIOLOGY RESULTS*****

Patients with suspected TB should be risk assessed, and preferably admitted to a side-room whilst this assessment is made. The risk assessment should include:

- the likelihood of infectiousness
- the likelihood of MDR-TB.

5.2.1. How Infectious?

Infectious TB is active tuberculous disease that presents a risk of transmission of infection to others. For most practical purposes, this means **sputum-smear positive pulmonary tuberculosis** in which acid-fast bacilli (AFB) are present on direct microscopy of sputum (also known as **open pulmonary TB**).

Sputum microscopy results available.

If acid-fast bacilli (AFB) are present on direct microscopy of the patient's sputum the patient has infectious TB and should be isolated appropriately.
Please see section 5.3.

NB: Patients whose bronchial washings are positive on direct microscopy should be managed as infectious TB if:

- their sputum is smear positive also,
- they are on a ward with immunocompromised patients or
- they are known or suspected as having MDR-TB

Sputum microscopy results not available

If the sputum microscopy result is not yet available the likelihood of infectiousness should be based on epidemiology, clinical & radiological findings, and the presence of coughing.

Degree of infectivity after treatment

A patient with infectious TB may be considered non-infectious after 2 weeks of treatment assuming that they are compliant and responding to treatment (except patients with MDR-TB).

NB: Patients with suspected or confirmed TB should **not** be nursed in the same area as immunocompromised patients (i.e., Laurel 2 and Laurel 3).

5.2.2. Likelihood of MDR-TB

An assessment to determine the risk of the patient being infected with a MDR strain of *M. tuberculosis* must be made by the admitting clinical team for each new diagnosis of TB, as these patients will be treated differently.

Risk Factors for MDR-TB

Assess the likelihood of a patient having MDR-TB based on the risk factors listed below (in order of greatest to least importance) and on the geographical distribution of drug resistance within the UK.

Major Risk Factors

- A history of prior TB drug treatment or treatment failure
- Contact with a known case of drug-resistant TB.
- Birth in a foreign country, particularly those with a high-incidence of MDR-TB (Appendix A).
- Any patient with suspected or confirmed TB who shows no improvement after 5-7 days of monitored treatment with standard quadruple anti-tuberculous therapy.

Minor Risk Factors

- HIV infection
- Residence in London
- Age profile, with highest rates between ages 25 and 44
- Male gender

If MDR-TB suspected

If based on this risk assessment, MDR-TB is suspected:

1. Inform the IPCT.
2. The patient should be isolated in a **monitored negative pressure ventilated side room** (see isolation and bed management policy). If none are available, the patient must be transferred to a hospital that has these facilities.
3. Refer the patient to a chest physician as soon as possible. Several second or third line agents will be used to treat these patients.
4. Inform the duty microbiologist so that rapid testing for rifampicin resistance can be arranged where appropriate.
5. Health care workers should wear personal protective equipment including FFP3 masks whilst caring for the patient. (See section 5.5 for further details).
6. Visitors should wear FFP3 masks when visiting the patient and have supervised donning and doffing – this should be documented in the patient's medical notes.

5.3. Isolation of Suspected and Confirmed Tuberculosis Cases

Please also see Appendix E.

People with TB at any site of disease should not be admitted to hospital for diagnostic tests or for care unless there is a clear clinical or socio-economic need e.g., homelessness. Infectious TB patients who require admission must be isolated as outlined below to prevent secondary cases in hospital.

Please see the Trust Isolation and Bed Management (WAHT-INF-045) policy also.

5.3.1. Levels of Isolation Required

Three levels of isolation are available:

Monitored negative pressure rooms.

These rooms are under negative pressure in relation to the ward. There are negative pressure rooms on Avon 3 or Laurel 2. They should have air pressure measured as defined by the Department of Health [DoH] (2013). Rooms with specialist ventilation must have doors and windows closed to be effective.

PLEASE NOTE: A switchable ventilated room is available on ITU but this **MUST BE SWITCHED TO NEGATIVE PRESSURE** not positive.

Single en-suite rooms

These rooms are not in negative pressure but are vented to the outside of the building. Most wards have these rooms.

*Patients with TB should **NOT** be admitted to rooms on the haematology/oncology ward.*

Beds on general ward areas


These are beds on a ward with standard ventilation.

5.3.2. Allocation of Isolation Facilities

Following a risk assessment to determine infectivity and the risk of MDR-TB (see sections 5.2.1 and 5.2.2), patients are allocated the appropriate level of isolation. This is summarised in figure 1.

- Patients with suspected or known infectious MDR-TB who are admitted to hospital should be admitted to a negative pressure room. If none are available, the patient must be transferred to a hospital that has these facilities.
- Patients with suspected or known respiratory TB should be separated from immunocompromised patients, either by admission to a single room on a separate ward or in a negative pressure room on the same ward (as a last resort).
- Patients with non-pulmonary TB may be nursed on a general ward. An exception to this is when performing aerosol-generating procedures such as abscess irrigation.

Figure 1: Flow chart demonstrating risk assessment of patients with Tuberculosis and allocation of isolation facilities.



* Contact duty microbiologist to discuss and refer to chest physician
 ** See section 5.2.2 for risk assessment
 *** Avoid wards with immunocompromised patients

5.3.3. Length of Isolation Precautions

Patients without MDR-TB

Smear positive TB patients without risk factors for MDR TB should be cared for in an appropriate single en-suite isolation room until:

- they have completed 2 weeks of the standard anti-tuberculous drug regimen with full adherence to treatment and demonstrated a clinical response.

OR

- they are discharged from hospital.

Criteria for cessation of segregation from immunocompromised patients:

- a minimum of two weeks of appropriate treatment as above

AND

- a minimum of three negative sputum smears on microscopy on separate occasions over a 14-day period (if originally smear positive).

AND EITHER

- complete resolution of cough

OR

- definitive clinical improvement e.g., remaining afebrile for a week.

Patients with suspected MDR-TB

Patients with suspected MDR-TB should be cared for in a negative pressure isolation room until:

- the patient is found not to have MDR-TB when results become available.

OR

- the patient is no longer considered to be infectious. This is usually when cultures are negative. **The TB physician in charge of the patient and the IPCT will determine this.**

Transfer of patients during isolation period

When leaving their isolation room (e.g., to have a chest x-ray), patients with smear-positive TB or MDR-TB should wear a standard surgical facemask until returned to isolation (NOT a valved FFP3 mask as these are designed to protect the wearer not vice versa).

If a patient is transferred to another ward or department (e.g., radiology, theatres etc) the unit must be informed of the patient's condition prior to transfer so that appropriate precautions can be undertaken.

5.3.4. Patients Requiring Ventilation/General Intensive Care Unit

These patients must be isolated in the NEGATIVE PRESSURE isolation room available on the ITU. If this is a switchable room; please ensure it is **SWITCHED TO NEGATIVE PRESSURE not positive.**

A closed ventilation system must be used. Use of an oscillator should be avoided as this is not a closed system and use of such a system would place neighbouring patients and staff at risk of infection.

Bronchoscopies should only be performed in a negatively ventilated room after appropriate advice from the IPCT and TB physician.

5.3.5. Other Infection Control Issues During Isolation Period

5.3.5.1. Crockery

Separate crockery is not necessary and is to be treated the same as all other crockery i.e., washed in the dishwasher or returned to the catering department for washing.

5.3.5.2. Coughing

If the patient is coughing, the patient should be encouraged to cover their mouth and cough into a disposable tissue. **See section 5.5 for HCW protection when patient coughing.**

5.3.5.3. Waste

All body fluids, including sputum, must be disposed of as clinical waste for incineration. Fluid such as pleural fluid should be sealed in a yellow bin. Sputum pots and tissues must be disposed of as clinical waste in yellow bags. A clinical waste bag should be available for the patient to dispose of such items directly.

Please see Trust Management of Healthcare Waste Policy for further information.

5.3.5.4. Bodies

If a patient with suspected or confirmed TB dies the body must be placed in a body bag. The mortuary staff should be informed via the telephone and on the 'Deceased Patient Details Tag' regarding the patient's infection so that appropriate infection control precautions can be taken in the mortuary.

5.4. Bronchoscopy and Other Aerosol Generating Procedures (AGPs)

For all patients with known or suspected TB, nebuliser treatment or aerosol generating procedures e.g., bronchoscopy, sputum induction should be carried out in an appropriately engineered negatively ventilated area (NICE, 2016) . Staff should wear appropriate personal protective equipment (see section 5.5). FFP 3 masks should be available in bronchoscopy.

NB: sputum induction is generally not advised due to the infection risk. Bronchoscopy is preferable.

5.5. HCWs Protection

5.5.1. Personal Protective Equipment (PPE)

Masks, gloves, and aprons are not needed for routine care of patients with TB unless:

- The patient is coughing uncontrollably, nebuliser treatment is required, or aerosol-inducing procedures are being performed e.g., bronchoscopy, sputum induction, irrigation of tuberculous abscess.
- Sputum contaminated items are being handled.
- MDR-TB is suspected or confirmed.

Staff and Visitors should wear FFP3 masks meeting the standards of the Health and Safety Executive (9) during contact with a patient with suspected or known MDR TB (NICE, 2016). These masks should be formally fit tested for staff before use and a certificate should be provided. It is the responsibility of the Nurse in Charge of the ward to ensure that visitors are wearing their masks correctly and donning/doffing of the FFP3 is supervised and documented in the patient's medical notes on each occasion. **See section 5.6 - Visitors.**

PLEASE NOTE: Valved FFP3 masks should **NOT** be worn by patients with TB. Standard surgical masks are available for patients when leaving their isolation rooms.

5.5.2. Occupational Health/Staff Vaccination

HCWs who have contact with infectious patients or their specimens should have the following before employment is commenced:

1. A pre-employment screen (questionnaire & interview)
2. BCG vaccination.
3. Information regarding symptoms of TB

Only staff who have evidence of some immunity on skin testing or who have had a BCG vaccination should care for patients with tuberculosis. Immunocompromised staff should not work in these areas.

All HCWs are advised to report to occupational health if they have a cough that lasts for more than three weeks or other symptoms that may be consistent with TB such as weight loss or night sweats. Any HCW with suspected TB should avoid work until TB is excluded or appropriate therapy given.

Annual reminders of TB symptoms should be provided to all HCWs within the Trust.

Further information may be obtained from the OHD.

5.5.3. Postmortems/Mortuary Staff

The mortuary will not routinely undertake post-mortem on known TB patients. However, if a postmortem is required, mortuary staff must be informed if the patient is suspected or confirmed to have TB so that appropriate precautions can be taken. These include use of FFP3 masks, gowns, double gloves, eye protection and the autopsy should be performed in an appropriately ventilated area. For further information please consult the mortuary policies.

If TB is identified on postmortem from a positive culture, the CCDC will be notified by the Microbiology Laboratory who in turn will notify the Pathologist and Clinician previously caring for the patient. If the diagnosis is made by a histology sample (only), the CCDC should be notified by the Histopathologist. This is to enable contact tracing of close contacts if necessary.

5.6. Visitors

Visitors should be limited to those who have had recent contact with the patient prior to their illness (i.e., household contacts). These visitors will have already been exposed to TB and will be screened by the TB nursing team. This restriction should continue until isolation is no longer necessary (see section 5.3.3).

In cases of MDR-TB advice should be sought from the TB physician or consultant microbiologist. Visitors to these patients should wear FFP3 masks during contact with the patient. They should be made aware of the risks associated with visiting.

Paediatric patients:

Visitors to a child admitted to hospital with suspected or confirmed TB should be screened as part of contact tracing and kept separate from other patients until they have been excluded as a source of infection (NICE, 2016).

Children or immunocompromised people should not visit a patient with infectious TB.

5.7. Contact Tracing

5.7.1. Community

The TB Specialist Nurses will undertake contact tracing in the community. They should therefore be informed of a case as soon as a new diagnosis is made.

Telephone: Ext: 53137 or Direct Dial: 01562 512316

For cases in community hospitals (Worcestershire Health and Care NHS Trust) the Community IPCT should be informed also.

Telephone: 01386 502552.

5.7.2. Hospital

5.7.2.1. Hospital Patients

Following diagnosis of TB in a hospital setting (e.g., inpatient or HCW) the clinical team or occupational health department respectively must inform the IPCT so that a risk assessment of exposure to others may be undertaken. This risk assessment should consider:

- Degree of infectivity of the index case
- Length of time before the infectious patient was isolated.
- If other patients are unusually susceptible to infection
- The proximity of the contact.

The IPCT should call an incident meeting if the index case is a HCW or if there are many patients potentially exposed. The following should attend the meeting:

- TB Nurse Specialists,
- TB Lead Physician

- IPCT
- Consultant Microbiologist / Infection Control Doctor
- Director of Infection Prevention & Control (DIPC)
- UKHSA representative,
- Medical and Nursing representatives for the area in which the incident took place,
- Hospital managers (Medical & Nursing Director or representative)
- Communications manager
- Occupational health nurse or manager
- Secretarial and IT support.

Patients should be regarded as ‘at risk’ of infection if they spent more than eight (cumulative) hours in the same bay as an inpatient with sputum smear-positive TB who had a cough. If immunocompromised patients were present on the ward they should be placed as “at-risk” also.

The exposed patient’s GP and consultant should be informed so that appropriate follow up can take place should the patient present with symptoms consistent with TB in the future. The exposure should be documented in the patient’s notes. Please see appendices B and C for sample letters to the patient and their GP/consultant respectively.

Inpatients who had prolonged close exposure to an index case with infectious TB should be managed like a household contact with screening tests for TB, as guided by Public Health England.

5.7.2.2. Healthcare Workers (HCW)

Casual contact of HCW with a case of infectious TB is not considered to be high risk.

The following staff groups will be managed as close contacts of a case of tuberculosis.

HCW who have undertaken:

- mouth-to-mouth resuscitation without appropriate protection
- prolonged care of a high dependency patient
- repeated chest physiotherapy on a patient with undiagnosed respiratory tuberculosis.
- Immunocompromised staff

The occupational health department will undertake contact tracing of exposed HCWs. Please contact OHD for further guidance.

5.8. Notification of Suspected or Confirmed Cases

Please also see TB Quick action guide – appendix E.

5.8.1. Statutory Notification

All forms of TB must be notified under the Public Health Act 1984. The doctor making the diagnosis (suspected or confirmed) is legally responsible for this.

Notifications may be made in two ways:

1. In writing:

Standard notification forms are available from the UKHSA website (<https://www.gov.uk/government/publications/notifiable-diseases-form-for-registered-medical-practitioners>) which should be completed and sent to the local UKHSA Health protection team (HPT).

Address: UKHSA West Midlands HPT
Level 2 Zone 1
23 Stephenson Street
Birmingham
B2 4BH

2. By telephone:

Telephone 0344 225 3560 (option 2)

Out of Hours for Health Professionals Only: 01384 679 031

PLEASE NOTE:

This clinical notification is separate to the laboratory notification system therefore it is the responsibility of the patient's team to submit these.

5.8.2. TB Nurse Specialists

Liaison with the TB Specialist Nurses is necessary so that contact tracing and arrangements for discharge can be made. Please inform the TB Service prior to discharge from hospital:

Telephone: Ext: 53137 **or** Direct Dial: 01562 512316

Address: TB Specialist Nursing team,
Kidderminster Treatment Centre
Cardiac Rehab
C Block
Bewdley Rd
Kidderminster
Worcestershire
DY11 6RJ

5.9. Discharge Policy

Before discharge from hospital the TB nurse specialists must be informed (see section 5.8.2) so that arrangements for the supervision and administration of all anti-tuberculosis therapy can be made if necessary.

If the patient is of no fixed abode (homeless), early referral to the hospital homeless liaison person must be made when the patient is admitted, and a discharge-planning meeting must be put in place prior to patient discharge.

A copy of the discharge letter must be sent to the TB specialist nurses detailing the patient's medication and date of follow up appointment.

Isolation rooms must be terminally cleaned in accordance with the Trust Isolation and Bed Management Policy and Cleaning Policy (WAHT-INF-045 and WAHT-CG-494).

5.9.1. Patients with MDR-TB

Before the decision is made to discharge a patient with suspected or confirmed MDR-TB from hospital, secure arrangements for the supervision and administration of all anti-TB therapy should have been agreed with the patient and carers (NICE, 2016).

The decision to discharge a patient with suspected or known MDR-TB must be discussed with the IPCT, the duty microbiologist, the local TB team, and the CCDC (NICE, 2016).

6. Implementation

6.1 Plan for implementation

Action	Person responsible	Timescale
Launch to Matrons at Senior Nurses Meeting, Ward Sisters and Infection Prevention and Control Link Nurses at their relevant meetings for wider dissemination to ward and departmental nursing staff	Lead/Senior IP Nurse	
Launch to all clinical staff through Trust Brief	Lead/Senior IP Nurse/Consultant Microbiologist	
Launch to all medical colleagues via Clinical Directors and presentation at relevant speciality audit meetings if requested.	Deputy Director Infection Prevention and Control/Consultant Microbiologist	

6.2 Dissemination

Disseminated to	Timescale
Instruction to all clinical staff of revised policy via weekly Trust Brief.	
Ward and departmental based clinical staff via Infection Prevention and Control Link Nurses	
Updated protocol to be made available via Key Documents intranet site	

6.3 Training and awareness

It is a mandatory requirement that all new Trust employees must attend a Trust corporate induction programme, which includes infection prevention and control (IPC) training. It is the responsibility of the line manager to ensure that IPC issues are covered in all local inductions and that this is documented.

It is a mandatory requirement that all clinical and non-clinical staff update their IPC training annually, either by attendance at a formal session, or using and completing online or e-learning resources. It is the line manager's responsibility to ensure that this occurs.

Different modalities are available to facilitate compliance with mandatory training requirements. These include attendance at formal lectures, ad hoc teaching, and access to online training. Records of staff training are kept centrally on the ESR database, and locally by Directorates as required.

7. Monitoring and compliance

Compliance with this policy will be assessed as and when cases arise, by the IPCT and will form part of any Root Cause Analysis (RCA) and incident / outbreak report.

Trust Policy

Page/ Section of Key Document	Key control:	Checks to be carried out to confirm compliance with the Policy:	How often the check will be carried out:	Responsible for carrying out the check:	Results of check reported to: <i>(Responsible for also ensuring actions are developed to address any areas of non- compliance)</i>	Frequency of reporting:
	WHAT?	HOW?	WHEN?	WHO?	WHERE?	WHEN?
5.2	Management of suspected TB cases: Once decision to admit, patient has been discussed with Consultant ID Physician/Consultant TB Physician, Consultant Medical Microbiologist (CMM), Infection Prevention (IP) Nurse BEFORE moving the patient.	Check patient medical records, CMM clinical record and ICNet system	As part of the post case review	Incident report author	TIPCC through incident report, by exception where non-compliance indicated	On a case by case basis
5.3	Isolation of patients with suspected/confirmed pulmonary tuberculosis (TB)	Audit of A&E records, patient medical records and OASIS for ADT status change	As part of ongoing patient management review	A&E/Ward Sister and IP Nurse reviewing patient	Exception report to Lead IP Nurse – this would then be reported to either outbreak committee if relevant or TIPCC	On a case by case basis
5.3 – 5.6	Compliance with protocols for e.g. PPE use, equipment, linen and waste management, hand hygiene practices, cleaning of isolation facility protocols visitor control, handling of the deceased.	Observation of practices by any: IP Nurse, CMMs, Consultant ID Physician, Matron and Ward Sister	Within 12 - 24 hours of admission and repeated daily, if concerns identified or during clinical review visit.	IP Nurse, Ward Sister, Matron, CMMs, Consultant ID Physician	Immediate feedback to clinical team (medical, nursing and therapies). TIPCC through incident report, where non-compliance noted.	On a case by case basis

Tuberculosis (TB) in Hospital: Infection Prevention Policy

Trust Policy

Page/ Section of Key Document	Key control:	Checks to be carried out to confirm compliance with the Policy:	How often the check will be carried out:	Responsible for carrying out the check:	Results of check reported to: <i>(Responsible for also ensuring actions are developed to address any areas of non-compliance)</i>	Frequency of reporting:
	WHAT?	HOW?	WHEN?	WHO?	WHERE?	WHEN?
5.8	Notification of suspected or confirmed cases of TB	Audit of patient medical records and evidence of the completion of Statutory Notification Forms (as per the Public Health Act 1984).	As part of ongoing patient management review	Diagnosing clinician/CMMs	Immediate feedback to clinical team (medical). TIPCC through incident report where non-compliance noted.	On a case by case basis
5.9	Notification of the intent to discharge a patient with confirmed tuberculosis	Audit of patient medical records and evidence of referral to the TB Nurse Specialists	As part of ongoing patient management review	IP Nurse, Ward Sister, Matron, CMMs, Consultant ID Physician	Immediate feedback to clinical team (medical and nursing). TIPCC through incident report, where non-compliance noted.	On a case by case basis

8. Policy Review

To be reviewed every 3 years or when a new version of the NICE Guidance is published.

9. References

UK Health Security Agency [UKHSA] (2020) Annual Review (2020 data) Tuberculosis in the West Midlands. [Online] Available at:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1097492/TB-west-midlands-2020-data.pdf [Accessed 25.09.23].

UKHSA (2023) Tuberculosis in England. 2022 report. [Online] Available at:

<https://www.gov.uk/government/publications/tuberculosis-in-england-2022-report-data-up-to-end-of-2021> [Accessed 13.09.23]

Gandhi, N.R., Moll, A., Willem Sturm, A., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., and Friedland, G. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in rural South Africa. *Lancet*, 368 (9547):1575-80. DOI:

[https://doi.org/10.1016/s0140-6736\(06\)69573-1](https://doi.org/10.1016/s0140-6736(06)69573-1)

Raviglione, M.C. & Smith, I.M. (2007). XDR Tuberculosis – Implications for Global Public Health. *New England Journal of Medicine* 356 (7): 656-659. DOI: <https://doi.org/10.1056/nejmp068273>

Control and prevention of tuberculosis in the United Kingdom: code of Practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. *Thorax* 2000; 55:887-907

<http://dx.doi.org/10.1136/thorax.55.11.887>

National Institute of Clinical Excellence [NICE]. (2016). Tuberculosis [Online] Available at: www.nice.org.uk/guidance/ng33 [Accessed 25.09.23]

Department of Health [DoH] (2013). Isolation facilities for infectious patients in acute settings. HBN04-01 Supplement 1. [Online] Available at: https://www.england.nhs.uk/wp-content/uploads/2021/05/HBN_04-01_Supp_1_Final.pdf [Accessed 13.09.23]

Health and Safety Executive [HSE] Respiratory Protective Equipment at Work: A practical guide. HSG53. ISBN 0-7176-2904-X. (www.hsebooks.com)

World Health Organisation [WHO]. (2021). WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: background document. [Online] Available at:

<https://apps.who.int/iris/bitstream/handle/10665/341980/9789240029439-eng.pdf?sequence=1&isAllowed=y> [Accessed 13.09.23].

10. Background

10.1 Equality requirements

There is recognition that some ethnic groups and geographical populations are at greater risk of acquisition of tuberculosis.

Further information available in the findings of the equality impact assessment (Supporting Document 1)

10.2 Financial risk assessment

There are no financial risks associated with this policy.

Further information available in the findings of the financial risk assessment (Supporting Document 2)

10.3 Consultation

Contribution List

Key individuals involved in reviewing the document

Name	Designation
Lara Bailey	Senior Infection Prevention and Control Nurse

This key document has been circulated to the following individuals for consultation.

Designation
All Trust Consultant Microbiologists*
Infectious Diseases Physicians
TB Lead Physicians
All Members of the Infection Prevention and Control Team
All Members of the TB Nursing Team
All Members of the Occupational Health Team*
Mortuary/Pathology Manager*
Microbiology Laboratory Manager
Matron for TB Service
UKHSA Representatives
Paediatric TB Lead

*Indicates comments received

Circulated to the chair(s) of the following committee's / groups for comments.

Name	Committee
Ms Sarah Shingler	Trust Infection Prevention and Control Committee (TIPCC)

10.4 Approval Process

The final draft will be checked to ensure it complies with the correct format and that all supporting documentation has been completed.

The policy will be submitted to TIPCC for approval before document code and version number are confirmed and the policy is released for placement on the Trust intranet.

Tuberculosis (TB) in Hospital: Infection Prevention Policy		
WAHT-INF-***	Page 25 of 30	Version 7

Supporting Document 1 - Equality Impact Assessment Tool
 To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.



Herefordshire & Worcestershire STP - Equality Impact Assessment (EIA) Form
 Please read EIA guidelines when completing this form

Section 1 - Name of Organisation (please tick)

Herefordshire & Worcestershire STP		Herefordshire Council		Herefordshire CCG
Worcestershire Acute Hospitals NHS Trust	x	Worcestershire County Council		Worcestershire CCGs
Worcestershire Health and Care NHS Trust		Wye Valley NHS Trust		Other (please state)

Name of Lead for Activity	Julie Booth – Deputy DIPC
----------------------------------	----------------------------------

Details of individuals completing this assessment	Name	Job title	e-mail contact
	Lara Bailey	Senior Infection Prevention and Control Nurse Advisor	larabailey@nhs.net
Date assessment completed	25.09.2023		

Section 2

Activity being assessed (e.g. policy/procedure, document, service redesign, policy, strategy etc.)	Title: Policy (Document) Tuberculosis (TB) in Hospital: Infection Prevention Policy
What is the aim, purpose and/or intended outcomes of this Activity?	This policy provides guidance on informing health professionals about TB which may pose a risk for spread of infection, and for

Trust Policy

	which control measures may be necessary (including vaccination).	
Who will be affected by the development & implementation of this activity?	<input type="checkbox"/> Service User <input type="checkbox"/> Patient <input type="checkbox"/> Carers <input type="checkbox"/> Visitors	<input type="checkbox"/> Staff
Is this:	<input type="checkbox"/> Review of an existing activity	
What information and evidence have you reviewed to help inform this assessment? (Please name sources, eg demographic information for patients / services / staff groups affected, complaints etc.)	National Guidance	
Summary of engagement or consultation undertaken (e.g. who and how have you engaged with, or why do you believe this is not required)	Key stakeholders have been engaged through the circulation of this policy prior to ratification being undertaken.	
Summary of relevant findings	No findings.	

Section 3

Please consider the potential impact of this activity (during development & implementation) on each of the equality groups outlined below. **Please tick one or more impact box below for each Equality Group and explain your rationale.** Please note it is possible for the potential impact to be both positive and negative within the same equality group and this should be recorded. Remember to consider the impact on e.g. staff, public, patients, carers etc. in these equality groups.

Equality Group	Potential positive impact	Potential neutral impact	Potential negative impact	Please explain your reasons for any potential positive, neutral or negative impact identified
Age		X		
Disability		X		
Gender Reassignment		X		
Marriage & Civil Partnerships		X		
Pregnancy & Maternity		X		

Equality Group	Potential positive impact	Potential <u>neutral</u> impact	Potential <u>negative</u> impact	Please explain your reasons for any potential positive, neutral or negative impact identified
Race including Traveling Communities		X		
Religion & Belief		X		
Sex		X		
Sexual Orientation		X		
Other Vulnerable and Disadvantaged Groups (e.g. carers; care leavers; homeless; Social/Economic deprivation, travelling communities etc.)		X		
Health Inequalities (any preventable, unfair & unjust differences in health status between groups, populations or individuals that arise from the unequal distribution of social, environmental & economic conditions within societies)		X		

Section 4


What actions will you take to mitigate any potential negative impacts?	Risk identified	Actions required to reduce / eliminate negative impact	Who will lead on the action?	Timeframe
How will you monitor these actions?				
When will you review this EIA? (e.g in a service redesign, this	When the quick guide requires revision in 3 years or if new guidance is published sooner.			

EIA should be revisited regularly throughout the design & implementation)

Section 5 - Please read and agree to the following Equality Statement

1. Equality Statement

- 1.1. All public bodies have a statutory duty under the Equality Act 2010 to set out arrangements to assess and consult on how their policies and functions impact on the 9 protected characteristics: Age; Disability; Gender Reassignment; Marriage & Civil Partnership; Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual Orientation
- 1.2. Our Organisations will challenge discrimination, promote equality, respect human rights, and aims to design and implement services, policies and measures that meet the diverse needs of our service, and population, ensuring that none are placed at a disadvantage over others.
- 1.3. All staff are expected to deliver services and provide services and care in a manner which respects the individuality of service users, patients, carer’s etc, and as such treat them and members of the workforce respectfully, paying due regard to the 9 protected characteristics.

Signature of person completing EIA	Lara Bailey
Date signed	25.09.23
Comments:	
Signature of person the Leader Person for this activity	
Date signed	30.10.2023 J Booth
Comments:	



Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

	Title of document:	Yes/No
1.	Does the implementation of this document require any additional Capital resources	No
2.	Does the implementation of this document require additional revenue?	No
3.	Does the implementation of this document require additional manpower?	No
4.	Does the implementation of this document release any manpower costs through a change in practice	No
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff.	No
	Other comments:	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval.